HK1256087A1 - 用於實體瘤靶向的雙特異性cart細胞 - Google Patents
用於實體瘤靶向的雙特異性cart細胞Info
- Publication number
- HK1256087A1 HK1256087A1 HK18115149.8A HK18115149A HK1256087A1 HK 1256087 A1 HK1256087 A1 HK 1256087A1 HK 18115149 A HK18115149 A HK 18115149A HK 1256087 A1 HK1256087 A1 HK 1256087A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cells
- solid tumor
- tumor targeting
- bispecific car
- bispecific
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562202698P | 2015-08-07 | 2015-08-07 | |
PCT/US2016/045360 WO2017027291A1 (en) | 2015-08-07 | 2016-08-03 | Bispecific car t-cells for solid tumor targeting |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1256087A1 true HK1256087A1 (zh) | 2019-09-13 |
Family
ID=57984403
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18115149.8A HK1256087A1 (zh) | 2015-08-07 | 2018-11-27 | 用於實體瘤靶向的雙特異性cart細胞 |
Country Status (9)
Country | Link |
---|---|
US (3) | US11458167B2 (zh) |
EP (1) | EP3331920A4 (zh) |
JP (2) | JP7162530B2 (zh) |
CN (1) | CN108174604B (zh) |
AU (2) | AU2016306209B2 (zh) |
CA (1) | CA2994829A1 (zh) |
HK (1) | HK1256087A1 (zh) |
MX (1) | MX2018001568A (zh) |
WO (1) | WO2017027291A1 (zh) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2016013144A (es) | 2014-04-10 | 2017-04-27 | Seattle Children's Hospital (Dba Seattle Children's Res Institute) | Metodo y composiciones para inmunoterapia celular. |
EP3331920A4 (en) * | 2015-08-07 | 2019-04-03 | Seattle Children's Hospital, dba Seattle Children's Research Institute | T CARRIER CARRIER CELLS FOR BISPECIFICATION OF SOLID TUMOR TARGETING |
DK3411393T3 (da) * | 2016-02-05 | 2021-06-28 | Hope City | Administration af manipulerede t-celler til behandling af cancere i centralnervesystemet |
CA3031559A1 (en) | 2016-08-02 | 2018-02-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof |
US11408005B2 (en) | 2016-12-12 | 2022-08-09 | Seattle Children's Hospital | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
CN111212849A (zh) * | 2017-06-30 | 2020-05-29 | 纪念斯隆-凯特林癌症中心 | 用于癌症的过继性细胞疗法的组合物和方法 |
CA3068641A1 (en) * | 2017-06-30 | 2019-01-03 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy |
CA3068634A1 (en) * | 2017-06-30 | 2019-01-03 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy for cancer |
JP7237926B2 (ja) * | 2017-07-31 | 2023-03-13 | レンティジェン・テクノロジー・インコーポレイテッド | 抗cd19/cd20免疫療法によりがんを処置するための組成物および方法 |
CN109423495A (zh) * | 2017-08-24 | 2019-03-05 | 上海恒润达生生物科技有限公司 | 一种双靶向嵌合抗原受体及其用途 |
CN111511391A (zh) | 2017-10-18 | 2020-08-07 | 英特拉克森公司 | 包含间隔区的多肽组合物 |
US20200354677A1 (en) * | 2017-11-01 | 2020-11-12 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
BR112020008638A2 (pt) * | 2017-11-01 | 2020-10-20 | Juno Therapeutics Inc | receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma) |
CN111683962A (zh) * | 2017-11-10 | 2020-09-18 | 美国政府(由卫生和人类服务部的部长所代表) | 靶向肿瘤抗原的嵌合抗原受体 |
WO2019111250A1 (en) * | 2017-12-05 | 2019-06-13 | The Medical Research Infrastructure And Health Services Fund Of The Tel Aviv Medical Center | T-cells comprising two different chimeric antigen receptors and uses thereof |
JP7437705B2 (ja) | 2017-12-05 | 2024-02-26 | ザ メディカル リサーチ, インフラストラクチャー, アンド ヘルス サーヴィシーズ ファンド オブ ザ テル アヴィヴ メディカル センター | 抗cd38及び抗cd138キメラ抗原受容体を含むt細胞、及びその用途 |
CN109970867B (zh) * | 2017-12-28 | 2022-10-18 | 上海细胞治疗研究院 | 一种cd40双向激活共刺激分子受体及其用途 |
CN109970866B (zh) * | 2017-12-28 | 2022-10-04 | 上海细胞治疗研究院 | 一种cd28双向激活共刺激分子受体及其用途 |
CN109970864A (zh) * | 2017-12-28 | 2019-07-05 | 上海细胞治疗研究院 | 一种双向激活共刺激分子受体及其用途 |
US10561686B2 (en) | 2018-01-12 | 2020-02-18 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
JP2021510540A (ja) * | 2018-01-11 | 2021-04-30 | イノベイティブ セルラー セラピューティクス インク.Innovative Cellular Therapeutics Inc. | 修飾細胞の増幅およびその応用 |
US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
GB201807862D0 (en) * | 2018-05-15 | 2018-06-27 | Ucl Business Plc | Chimeric antigen receptor |
WO2019222579A1 (en) * | 2018-05-17 | 2019-11-21 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors with myd88 and cd40 costimulatory domains |
KR20210018323A (ko) | 2018-06-06 | 2021-02-17 | 매사추세츠 인스티튜트 오브 테크놀로지 | 진핵 세포에서의 번역을 위한 원형 rna |
CN112334572A (zh) * | 2018-06-19 | 2021-02-05 | 南特细胞公司 | Hiv治疗组合物和方法 |
EP3820888A4 (en) * | 2018-07-13 | 2022-04-27 | Nanjing Legend Biotech Co., Ltd. | CO-RECEPTOR SYSTEMS FOR THE TREATMENT OF INFECTIOUS DISEASES |
CN108948211B (zh) * | 2018-07-24 | 2021-08-20 | 北京美康基免生物科技有限公司 | 一种基于靶向gd2的嵌合抗原受体及其应用 |
AU2019315440A1 (en) * | 2018-07-30 | 2021-02-18 | University Of Southern California | Improving the efficacy and safety of adoptive cellular therapies |
WO2020033430A1 (en) * | 2018-08-08 | 2020-02-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-2 and uses thereof |
CN110845621A (zh) * | 2018-08-21 | 2020-02-28 | 上海恒润达生生物科技有限公司 | 一种靶向egfr和cd19双靶点的嵌合抗原受体方法 |
US20220042039A1 (en) * | 2018-08-28 | 2022-02-10 | Pharos Vaccine Inc. | Improved lentiviral vector |
US20220348682A1 (en) | 2018-08-30 | 2022-11-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
CN109503716B (zh) * | 2018-10-08 | 2021-04-27 | 浙江生研生物科技有限公司 | 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用 |
CN109266618B (zh) * | 2018-10-18 | 2021-04-23 | 赛元生物科技(杭州)有限公司 | 能够靶向肿瘤细胞的巨噬细胞及其制备方法 |
CN109400710A (zh) * | 2018-11-02 | 2019-03-01 | 山西大医院(山西医学科学院) | 一种靶向kif20a阳性胰腺癌双特异性抗体及其制备方法和应用 |
SG11202105238YA (en) * | 2018-11-19 | 2021-06-29 | Univ Texas | Suicide gene |
US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
US20240025963A1 (en) * | 2018-12-14 | 2024-01-25 | 2Seventy Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
CN111748017A (zh) * | 2019-03-26 | 2020-10-09 | 上海瑞可新生物科技有限公司 | 一种抗原多肽及其表达载体、组合药物、试剂盒和应用 |
WO2020210768A1 (en) * | 2019-04-12 | 2020-10-15 | The Trustees Of The University Of Pennsylvania | Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins |
CA3138276A1 (en) * | 2019-04-30 | 2020-11-05 | Atara Biotherapeutics, Inc. | Antigen specific cd19-targeted car-t cells |
KR20220016083A (ko) | 2019-04-30 | 2022-02-08 | 센티 바이오사이언시스, 인코포레이티드 | 키메라 수용체 및 이의 사용 방법 |
EP3965897A4 (en) * | 2019-05-07 | 2023-01-04 | The Board of Trustees of the Leland Stanford Junior University | CHIMERA ANTIGEN RECEPTORS TARGETED AGAINST GLYPICAN-2 |
WO2020237227A1 (en) | 2019-05-22 | 2020-11-26 | Massachusetts Institute Of Technology | Circular rna compositions and methods |
US20200384029A1 (en) * | 2019-06-07 | 2020-12-10 | The Trustees Of The University Of Pennsylvania | Dual car expressing t cells individually linked to cd28 and 4-1bb |
CN114555815A (zh) * | 2019-07-30 | 2022-05-27 | 大学健康网络 | T细胞受体及其使用方法 |
EP4021464A4 (en) * | 2019-08-27 | 2024-01-03 | The Trustees of The University of Pennsylvania | SYNTHETIC CARS FOR TREATING IL13Ra2 POSITIVE HUMAN OR CANINE TUMORS |
TW202134278A (zh) * | 2019-11-08 | 2021-09-16 | 美商胡曼尼根公司 | 用於治療腫瘤之epha3導向car-t細胞 |
CN115052635A (zh) | 2019-12-04 | 2022-09-13 | 奥纳治疗公司 | 环状rna组合物和方法 |
CN113106067B (zh) * | 2020-01-10 | 2024-06-21 | 南京大学 | 一种嵌合抗原受体-单核/巨噬细胞(car-m)的构建及其应用 |
CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技(香港)有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
EP3892720A1 (en) * | 2020-04-06 | 2021-10-13 | Innovative Cellular Therapeutics Holdings, Ltd. | Presenting cell and use thereof in cell therapy |
KR20230025662A (ko) * | 2020-05-05 | 2023-02-22 | 리제너론 파마슈티칼스 인코포레이티드 | Cd28 제타 및 cd3 제타를 포함하는 car |
WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
EP4259285A1 (en) * | 2020-12-09 | 2023-10-18 | Affyimmune Therapeutics, Inc. | Dual chimeric antigen receptor targeting epcam and icam-1 |
CN114685683A (zh) * | 2020-12-31 | 2022-07-01 | 博生吉医药科技(苏州)有限公司 | 靶向gd2的car-t细胞及其制备和应用 |
WO2023168436A1 (en) * | 2022-03-03 | 2023-09-07 | Board Of Regents, The University Of Texas System | Anti-cd19 and anti-cd79b chimeric antigen receptors and methods of use thereof |
CN114573711A (zh) * | 2022-03-04 | 2022-06-03 | 陕西师范大学 | 一种TanCAR的构建及其应用 |
CN114605560B (zh) * | 2022-03-30 | 2024-02-20 | 江苏蒙彼利生物科技有限公司 | 一种car-nk细胞及其制备方法与应用 |
WO2024026505A2 (en) * | 2022-07-29 | 2024-02-01 | Amit Patel | Disruption of telocyte activity |
WO2024059733A2 (en) * | 2022-09-14 | 2024-03-21 | Fred Hutchinson Cancer Center | Chimeric antigen receptors binding nectin-4 |
WO2024097911A1 (en) * | 2022-11-02 | 2024-05-10 | Fate Therapeutics, Inc. | Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting gprc5d |
CN117338914A (zh) * | 2023-10-27 | 2024-01-05 | 中山市珈钰生物医药有限公司 | 一种同种异体树突细胞肿瘤疫苗及其制备方法和应用 |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU650085B2 (en) | 1990-11-13 | 1994-06-09 | Immunex Corporation | Bifunctional selectable fusion genes |
US20020111474A1 (en) | 1990-12-14 | 2002-08-15 | Capon Daniel J. | Chimeric chains for receptor-associated signal transduction pathways |
EP0650367A4 (en) | 1992-06-01 | 1998-04-15 | New England Medical Center Inc | BLOCKING OF INTERCELLULAR INTERACTIONS WITH CD43 CHEMICAL MOLECULES. |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US6660257B1 (en) | 1996-10-25 | 2003-12-09 | Pharmacia Corporation | Circular permuteins of flt3 ligand |
AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
GB0015119D0 (en) | 2000-06-20 | 2000-08-09 | Angeletti P Ist Richerche Bio | Methods and means for regulation of gene expression |
AU7025201A (en) | 2000-07-03 | 2002-01-14 | Gala Design Inc | Expression vectors |
ATE338124T1 (de) | 2000-11-07 | 2006-09-15 | Hope City | Cd19-spezifische umgezielte immunzellen |
US7148321B2 (en) | 2001-03-07 | 2006-12-12 | Emd Lexigen Research Center Corp. | Expression technology for proteins containing a hybrid isotype antibody moiety |
US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
WO2002097099A1 (en) | 2001-05-29 | 2002-12-05 | Valentis, Inc. | Regulated expression of ghrh |
WO2003025228A1 (en) | 2001-09-18 | 2003-03-27 | Proteologics, Inc. | Methods and compositions for treating hcap associated diseases |
US20030148982A1 (en) | 2001-11-13 | 2003-08-07 | Brenner Malcolm K. | Bi-spcific chimeric T cells |
WO2003087338A2 (en) | 2002-04-11 | 2003-10-23 | Amgen, Inc. | Her-2 receptor tyrosine kinase molecules and uses thereof |
WO2004029284A2 (en) | 2002-09-30 | 2004-04-08 | Protein Design Labs, Inc. | Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes |
US20040158329A1 (en) | 2003-02-10 | 2004-08-12 | Waldemar Link (Gmbh & Co.) | Hip joint prosthesis with shaft inserted into femur |
ATE472338T1 (de) | 2003-02-20 | 2010-07-15 | Seattle Genetics Inc | Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs |
US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
WO2004092338A2 (en) | 2003-04-11 | 2004-10-28 | Diadexus, Inc. | Compositions, splice variants and methods relating to cancer specific genes and proteins |
US20070166318A1 (en) | 2003-05-30 | 2007-07-19 | Macina Roberto A | Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins |
KR101141507B1 (ko) | 2003-07-21 | 2012-05-08 | 이스티투토 디 리세르쉐 디 비올로지아 몰레콜라레 피. 안젤레티 에스.알.엘. | 사람 상피 성장 인자 2/neu 항원을 암호화하는 합성 유전자 및 이를 포함하는 약제학적 조성물 |
CA2543329A1 (en) | 2003-10-24 | 2005-05-06 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Orthogonal gene switches |
US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
US8071364B2 (en) | 2003-12-24 | 2011-12-06 | Transgenrx, Inc. | Gene therapy using transposon-based vectors |
US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
US7910101B2 (en) | 2004-10-25 | 2011-03-22 | Centocor, Inc. | Melanocortin receptor binding mimetibodies, compositions, methods and uses |
AU2006327175A1 (en) | 2005-12-21 | 2007-06-28 | Medimmune, Llc | Epha2 bite molecules and uses thereof |
WO2007137267A2 (en) | 2006-05-22 | 2007-11-29 | Hiprocell, Llc | Protein production using eukaryotic cell lines |
WO2008012237A1 (en) | 2006-07-24 | 2008-01-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Multi-antigen construct and uses thereof |
US7709253B2 (en) | 2006-08-04 | 2010-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists |
CN101828113B (zh) | 2007-07-25 | 2014-04-16 | 德国弗劳恩霍夫协会债权安格万特学术研究所 | 自结合重组抗体融合蛋白 |
WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
DK2279253T3 (en) | 2008-04-09 | 2017-02-13 | Maxcyte Inc | Construction and application of therapeutic compositions of freshly isolated cells |
JP2012501180A (ja) | 2008-08-26 | 2012-01-19 | シティ・オブ・ホープ | T細胞の抗腫瘍エフェクター機能増進のための方法および組成物 |
CN105624193B (zh) | 2008-09-26 | 2021-07-13 | 索元生物医药(美国)有限公司 | 重组载体 |
US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
US8329882B2 (en) | 2009-02-18 | 2012-12-11 | California Institute Of Technology | Genetic control of mammalian cells with synthetic RNA regulatory systems |
EP2438443A4 (en) | 2009-06-02 | 2012-07-25 | Targeted Molecular Diagnostics Llc | METHOD FOR DETECTING AND QUANTIFYING THE P95 COMPONENT OF HER2 / NEU (ERBB2) |
US8075895B2 (en) | 2009-09-22 | 2011-12-13 | Janssen Pharmaceutica N.V. | Identification of antigenic peptides from multiple myeloma cells |
HUE044461T2 (hu) | 2009-11-03 | 2019-10-28 | Hope City | Csonkolt epidermális növekedési faktor receptor (EGFRT) transzdukált T-sejt szelekcióhoz |
JP5285678B2 (ja) | 2010-06-18 | 2013-09-11 | 株式会社エヌ・ティ・ティ・ドコモ | 移動通信方法及びコアネットワーク装置 |
NO3012268T3 (zh) | 2010-09-08 | 2018-04-14 | ||
TR201820015T4 (tr) | 2010-12-09 | 2019-01-21 | Univ Pennsylvania | Kanser Tedavisi İçin Kimerik Antijen Reseptörü-Modifiye Edilmiş T Hücrelerinin Kullanılması |
EA201391059A1 (ru) | 2011-01-18 | 2014-05-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Композиции для лечения рака и способы их применения |
NZ743310A (en) | 2011-03-23 | 2022-11-25 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
JP2014514927A (ja) | 2011-04-13 | 2014-06-26 | イミュニカム・エイビイ | 抗原特異的t細胞の増殖のための方法 |
EP3683319A1 (en) | 2011-06-01 | 2020-07-22 | Precision Biosciences, Inc. | Methods and products for producing engineered mammalian cell lines with amplified transgenes |
CA2835772C (en) | 2011-06-22 | 2020-12-01 | F. Hoffmann-La Roche Ag | Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes |
DE102011118018B4 (de) | 2011-10-25 | 2017-10-26 | Plasmidfactory Gmbh & Co. Kg | Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen |
WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
CA2861491C (en) * | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
ITRM20120058A1 (it) | 2012-02-20 | 2013-08-21 | Pisanelli Giovanni Codacci | Famiglia di molecole a base di zuccheri ad uso terapeutico e relativo procedimento di produzione |
EP3747898B1 (en) | 2012-02-22 | 2023-03-15 | The Trustees of the University of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
CA2869562C (en) | 2012-04-11 | 2023-09-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
US9540657B2 (en) | 2012-05-25 | 2017-01-10 | California Institute Of Technology | Expression of secreted and cell-surface polypeptides |
WO2013181440A1 (en) | 2012-05-30 | 2013-12-05 | Baylor College Of Medicine | Supercoiled minivectors as a tool for dna repair, alteration and replacement |
EP2669378A1 (en) | 2012-05-31 | 2013-12-04 | Helmut Hanenberg | Cytochrome P450 suicide gene system |
CN104350709B (zh) | 2012-06-01 | 2018-03-13 | 日本电气株式会社 | 交换机***、线路卡、交换卡、fdb学习方法及fdb学习调停方法 |
IL293944A (en) * | 2012-08-20 | 2022-08-01 | Hutchinson Fred Cancer Res | Method and preparations for cellular immunotherapy |
WO2014039044A1 (en) | 2012-09-06 | 2014-03-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t memory stem cell populations |
CA2886859C (en) | 2012-10-02 | 2022-05-17 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
US10117896B2 (en) * | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
US20150329640A1 (en) | 2012-12-20 | 2015-11-19 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
ES2671004T3 (es) | 2013-03-07 | 2018-06-04 | Baylor College Of Medicine | Dirección a CD138 en cáncer |
EP2777711A1 (en) | 2013-03-11 | 2014-09-17 | Icon Genetics GmbH | Her2/Neu cancer vaccine |
TWI654206B (zh) | 2013-03-16 | 2019-03-21 | 諾華公司 | 使用人類化抗-cd19嵌合抗原受體治療癌症 |
AU2014268364A1 (en) | 2013-05-24 | 2015-12-10 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
CA2929087A1 (en) * | 2013-10-31 | 2015-05-07 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
DK3071223T3 (da) | 2013-11-21 | 2021-03-29 | Autolus Ltd | Cell |
EP3808410A1 (en) * | 2013-12-20 | 2021-04-21 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
WO2015105522A1 (en) | 2014-01-13 | 2015-07-16 | Forman Stephen J | Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use |
SG10201811816RA (en) | 2014-02-14 | 2019-02-27 | Univ Texas | Chimeric antigen receptors and methods of making |
JP2017513818A (ja) | 2014-03-15 | 2017-06-01 | ノバルティス アーゲー | キメラ抗原受容体を使用する癌の処置 |
MX2016013144A (es) | 2014-04-10 | 2017-04-27 | Seattle Children's Hospital (Dba Seattle Children's Res Institute) | Metodo y composiciones para inmunoterapia celular. |
US10604740B2 (en) | 2014-05-14 | 2020-03-31 | Carsgen Therapeutics Limited | Nucleic acids encoding chimeric antigen receptor proteins which bind epidermal growth factor receptor and T lymphocyte expressing the protein |
JP6797693B2 (ja) | 2014-06-02 | 2020-12-09 | アメリカ合衆国 | Cd−19を標的とするキメラ抗原受容体 |
TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
MX2017005344A (es) | 2014-10-27 | 2017-08-15 | Hutchinson Fred Cancer Res | Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva. |
GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
JP2018515123A (ja) | 2015-05-18 | 2018-06-14 | ティーシーアール2 セラピューティクス インク. | 融合タンパク質を用いたtcrの再プログラミングのための組成物及び方法 |
EP4272757A3 (en) | 2015-06-10 | 2023-12-27 | ImmunityBio, Inc. | Modified nk-92 cells for treating cancer |
AU2016277121C1 (en) | 2015-06-12 | 2022-07-14 | Lentigen Technology, Inc. | Method to treat cancer with engineered T-cells |
EP3331920A4 (en) | 2015-08-07 | 2019-04-03 | Seattle Children's Hospital, dba Seattle Children's Research Institute | T CARRIER CARRIER CELLS FOR BISPECIFICATION OF SOLID TUMOR TARGETING |
DK3411393T3 (da) | 2016-02-05 | 2021-06-28 | Hope City | Administration af manipulerede t-celler til behandling af cancere i centralnervesystemet |
CN109415409B (zh) | 2016-04-01 | 2022-03-15 | 亘喜生物科技(上海)有限公司 | Flag标记的cd19-car-t细胞 |
EP3518972A4 (en) | 2016-09-28 | 2020-07-22 | Kite Pharma, Inc. | ANTIGEN BINDING MOLECULES AND THEIR METHODS OF USE |
EP3523326B1 (en) | 2016-10-04 | 2020-06-03 | Precision Biosciences, Inc. | Co-stimulatory domains for use in genetically-modified cells |
US11408005B2 (en) | 2016-12-12 | 2022-08-09 | Seattle Children's Hospital | Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells |
JOP20180042A1 (ar) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام |
US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
US11104732B2 (en) | 2019-04-24 | 2021-08-31 | Innovative Cellular Therapeutics Holdings, Ltd. | Reducing immune inhibition induced by SIGLEC-15 |
-
2016
- 2016-08-03 EP EP16835650.9A patent/EP3331920A4/en active Pending
- 2016-08-03 CA CA2994829A patent/CA2994829A1/en active Pending
- 2016-08-03 JP JP2018506286A patent/JP7162530B2/ja active Active
- 2016-08-03 US US15/750,708 patent/US11458167B2/en active Active
- 2016-08-03 CN CN201680058143.5A patent/CN108174604B/zh active Active
- 2016-08-03 AU AU2016306209A patent/AU2016306209B2/en active Active
- 2016-08-03 WO PCT/US2016/045360 patent/WO2017027291A1/en active Application Filing
- 2016-08-03 MX MX2018001568A patent/MX2018001568A/es unknown
-
2018
- 2018-11-27 HK HK18115149.8A patent/HK1256087A1/zh unknown
-
2020
- 2020-11-03 US US17/088,005 patent/US11123369B2/en active Active
-
2022
- 2022-04-20 JP JP2022069615A patent/JP2022119759A/ja active Pending
- 2022-09-12 US US17/931,258 patent/US20230130938A1/en active Pending
-
2023
- 2023-10-05 AU AU2023241321A patent/AU2023241321A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210085719A1 (en) | 2021-03-25 |
EP3331920A4 (en) | 2019-04-03 |
US20230130938A1 (en) | 2023-04-27 |
WO2017027291A1 (en) | 2017-02-16 |
CN108174604B (zh) | 2023-06-23 |
US11458167B2 (en) | 2022-10-04 |
AU2016306209B2 (en) | 2023-07-06 |
MX2018001568A (es) | 2019-04-25 |
AU2023241321A1 (en) | 2023-10-26 |
JP2018522567A (ja) | 2018-08-16 |
US20200215108A1 (en) | 2020-07-09 |
JP2022119759A (ja) | 2022-08-17 |
CN108174604A (zh) | 2018-06-15 |
CA2994829A1 (en) | 2017-02-16 |
US11123369B2 (en) | 2021-09-21 |
EP3331920A1 (en) | 2018-06-13 |
JP7162530B2 (ja) | 2022-10-28 |
AU2016306209A1 (en) | 2018-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1256087A1 (zh) | 用於實體瘤靶向的雙特異性cart細胞 | |
GB201621091D0 (en) | Convoy vehicle look-ahead | |
HK1250918A1 (zh) | 用於膠質母細胞瘤的egfr導向的car療法 | |
IL254700A0 (en) | Chimeric antigen receptor T-cells for the treatment of solid tumors expressing B.7-IZ.4 | |
PL3325323T3 (pl) | Pojazd szynowy | |
HK1245120A1 (zh) | 用於癌症的新治療 | |
GB2536002B (en) | Railway Vehicle Operation | |
HUE060564T2 (hu) | Jármû-architektúra | |
HUP1600666A1 (hu) | Szerkezeti elrendezés mozgó jármûvek mérlegelésére | |
GB2540634B (en) | Armoured vehicle | |
HK1250257A1 (zh) | 用於***疾病的生物標記物組合 | |
ZA201605349B (en) | Width-adjustable heavy-goods vehicle | |
PL3280628T3 (pl) | Pojazd szynowy | |
KR102220409B9 (ko) | 차량용 범퍼 | |
GB201510496D0 (en) | Vehicle | |
GB201515879D0 (en) | Vehicle mounted shield | |
ZA201603482B (en) | Power supplies for vehicles | |
AU201614568S (en) | Car | |
TWD174465S (zh) | 汽車之部分 | |
AU363422S (en) | Car | |
AU363423S (en) | Car | |
AU5552P (en) | USEVO1201 Evolvulus hybrid | |
GB201516204D0 (en) | Vehicles | |
GB201515858D0 (en) | Hybrid car | |
GB201517081D0 (en) | Predicting increased risk for sporadic cancer |